These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 28084107)

  • 1. The risk of gastrointestinal bleeding in patients receiving dabigatran etexilate: a systematic review and meta-analysis of the literature.
    Di Minno MN; Ambrosino P; Di Minno A; Tremoli E; Di Minno G
    Ann Med; 2017 Jun; 49(4):329-342. PubMed ID: 28084107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation.
    Pallisgaard JL; Gislason GH; Torp-Pedersen C; Lee CJ; Sindet-Pedersen C; Staerk L; Olesen JB; Lindhardt TB
    PLoS One; 2016; 11(8):e0161768. PubMed ID: 27560967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists.
    Carmo J; Moscoso Costa F; Ferreira J; Mendes M
    Thromb Haemost; 2016 Sep; 116(4):754-63. PubMed ID: 27465747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal timing of vitamin K antagonist resumption after upper gastrointestinal bleeding. A risk modelling analysis.
    Majeed A; Wallvik N; Eriksson J; Höijer J; Bottai M; Holmström M; Schulman S
    Thromb Haemost; 2017 Feb; 117(3):491-499. PubMed ID: 28004062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.
    Abraham NS; Noseworthy PA; Yao X; Sangaralingham LR; Shah ND
    Gastroenterology; 2017 Apr; 152(5):1014-1022.e1. PubMed ID: 28043907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding.
    Van der Wall SJ; Lopes RD; Aisenberg J; Reilly P; van Ryn J; Glund S; Elsaesser A; Klok FA; Pollack CV; Huisman MV
    Circulation; 2019 Feb; 139(6):748-756. PubMed ID: 30586692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation.
    Larsen TB; Gorst-Rasmussen A; Rasmussen LH; Skjøth F; Rosenzweig M; Lip GY
    Am J Med; 2014 Jul; 127(7):650-656.e5. PubMed ID: 24530792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal bleeding with dabigatran, a comparative study with warfarin: a multicenter experience.
    Sherid M; Sifuentes H; Sulaiman S; Samo S; Husein H; Tupper R; Spurr C; Sridhar S
    Korean J Gastroenterol; 2015 Apr; 65(4):205-14. PubMed ID: 25896154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy.
    Lauffenburger JC; Rhoney DH; Farley JF; Gehi AK; Fang G
    Pharmacotherapy; 2015 Jun; 35(6):560-8. PubMed ID: 26044889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Gastrointestinal Bleeding Among Dabigatran Users - A Self Controlled Case Series Analysis.
    Tang W; Chang HY; Zhou M; Singh S
    Sci Rep; 2017 Jan; 7():40120. PubMed ID: 28106053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dabigatran and vitamin K antagonists' use in naïve patients with non-valvular atrial fibrillation: a cross-sectional study of primary care-based electronic health records.
    Vlacho B; Giner-Soriano M; Zabaleta-Del-Olmo E; Roso-Llorach A; García-Sangenís A; Morros-Pedrós R
    Eur J Clin Pharmacol; 2017 Oct; 73(10):1323-1330. PubMed ID: 28725983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants.
    Caldeira D; Barra M; Ferreira A; Rocha A; Augusto A; Pinto FJ; Costa J; Ferreira JJ
    Aliment Pharmacol Ther; 2015 Dec; 42(11-12):1239-49. PubMed ID: 26434935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The assessment of anticoagulant activity to predict bleeding outcome in atrial fibrillation patients receiving dabigatran etexilate.
    Chang YT; Hu YF; Liao JN; Chern CM; Lin YJ; Chang SL; Wu CH; Sung SH; Wang KL; Lu TM; Chao TF; Lo LW; Hsu LC; Chung CP; Chang PM; Hsu WH; Chiou CW; Chen SA
    Blood Coagul Fibrinolysis; 2016 Jun; 27(4):389-95. PubMed ID: 26991859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of gastrointestinal bleeding with dabigatran: a head-to-head comparative study with rivaroxaban.
    Sherid M; Sifuentes H; Sulaiman S; Samo S; Husein H; Tupper R; Thiruvaiyaru D; Spurr C; Sridhar S
    Digestion; 2014; 90(2):137-46. PubMed ID: 25278002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Gastrointestinal bleeding during treatment with non­vitamin K antagonist oral anticoagulants (NOACs) may be caused by malignant lesions].
    Haeggström A; Risberg D; Al-Kahlili F; Gilstring Å; Tullberg U; Wallén H
    Lakartidningen; 2016 Nov; 113():. PubMed ID: 27824386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation.
    Ezekowitz MD; Wallentin L; Connolly SJ; Parekh A; Chernick MR; Pogue J; Aikens TH; Yang S; Reilly PA; Lip GY; Yusuf S;
    Circulation; 2010 Nov; 122(22):2246-53. PubMed ID: 21147728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].
    Saliba L; Mondoly P; Duparc A; Bura-Rivière A; Maury P; Calmels V; Sallerin B; Pathak A; Montastruc JL; Bagheri H
    Therapie; 2015; 70(6):485-92. PubMed ID: 26223162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Fatal bleeding diarrhoea during dabigatran etexilate therapy].
    Nyby S; Hennes O
    Ugeskr Laeger; 2014 Dec; 176(51):. PubMed ID: 25534224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.